Up to now, several TAAs have been reported as AML antigens against by CAR-T cells such as CD33 and CD123 [10], but previous CAR-T cell therapy trials in AML did not result in long-term responses and exhibited toxicity toward normal hematopoietic progenitor stem cells (HPSCs). Here, CD33 is linked to acute myeloid leukemia.